Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Anthera Pharmaceuticals Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Anthera Pharmaceuticals Inc 주요 수익원은 Energy Saving Solutions and Services이며, 최신 수익 발표에서 수익은 262,509입니다. 지역별로는 China이 Anthera Pharmaceuticals Inc의 주요 시장이며, 수익은 262,509입니다.
Anthera Pharmaceuticals Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Anthera Pharmaceuticals Inc의 순손실은 $0입니다.